Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Diphosphonates × Clear all
NCT01215344 2018-05-15

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
36 enrolled 8 charts
Plasma cell

Multiple Myeloma

NCT00091832 2014-01-28

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

Amgen

Phase 2 Completed
255 enrolled 34 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡